Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biocryst Pharma Inc
(NQ:
BCRX
)
4.450
-0.030 (-0.67%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Biocryst Pharma Inc
< Previous
1
2
3
4
5
6
Next >
2 Super-Charged Growth Stocks to Buy Now
October 13, 2021
These two small drugmakers are poised for a long-winded growth spurt.
Via
The Motley Fool
NICE Recommends BioCryst's Hereditary Angioedema Med
September 16, 2021
The U.K.'s National Institute for Health and Care Excellence (NICE) has recommended BioCryst Pharmaceuticals Inc's (NASDAQ: BCRX) Orladeyo (berotralstat)...
Via
Benzinga
US Government Exercises Option To Buy Additional Doses Of BioCryst's Flu Med
September 01, 2021
The U.S. Department of Health and Human Services (HHS) has exercised its option to purchase an additional 10,000 doses of BioCryst Pharmaceuticals Inc's (...
Via
Benzinga
The Daily Biotech Pulse: Early Approval For Ascendis' Pediatric Growth Hormone Deficiency Treatment, Redhill Biopharma Spikes On Positive COVID-19 Drug Data, RenovoRx IPO
August 26, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 25) Abbvie Inc. (NYSE: ABBV)...
Via
Benzinga
Exposures
COVID-19
Analyzing BioCryst Pharmaceuticals's Unusual Options Activity
August 11, 2021
BioCryst Pharmaceuticals (NASDAQ:BCRX) shares experienced...
Via
Benzinga
Analyzing BioCryst Pharmaceuticals's Unusual Options Activity
July 30, 2021
Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) saw some...
Via
Benzinga
Analyzing BioCryst Pharmaceuticals's Unusual Options Activity
August 16, 2021
BioCryst Pharmaceuticals (NASDAQ:BCRX) shares experienced unusual options activity on Monday. The stock price moved down to $15.44 following the option alert. Sentiment: BULLISH...
Via
Benzinga
BioCryst Stock Jumps After Pulling Out $200M Equity Raise
August 11, 2021
BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) has withdrawn its proposed public offering of $200 million of its stock and pre-funded warrants. The Company says...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
August 11, 2021
Gainers CohBar (NASDAQ:CWBR) stock moved upwards by 68.21% to $2.17 during Wednesday's pre-market session. The company's market cap stands at $134.0 million. The...
Via
Benzinga
22 Stocks Moving in Wednesday's Pre-Market Session
August 11, 2021
Gainers CohBar, Inc. (NASDAQ: CWBR) shares rose 78.3% to $2.30 in pre-market trading after the company reported results from the Phase 1a/1b study of CB4211 under development for...
Via
Benzinga
The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering
August 11, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Alnylam Pharmaceuticals,...
Via
Benzinga
Exposures
Product Safety
85 Biggest Movers From Yesterday
August 11, 2021
Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) jumped 125.3% to close at $18.77 on Tuesday after the company announced positive interim results from the Phase 1 trial with FTX...
Via
Benzinga
54 Stocks Moving In Tuesday's Mid-Day Session
August 10, 2021
Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) climbed 79.3% to $14.93 after the company announced positive interim results from the Phase 1 trial with FTX-6058 in healthy...
Via
Benzinga
28 Stocks Moving in Tuesday's Pre-Market Session
August 10, 2021
Gainers Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) shares rose 38.6% to $66.88 in pre-market trading after the company reported better-than-expected Q2 earnings and also...
Via
Benzinga
The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO
August 06, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 5) Alkermes plc (NASDAQ: ALKS)...
Via
Benzinga
BioCryst Pharmaceuticals (BCRX) Q2 2021 Earnings Call Transcript
August 06, 2021
BCRX earnings call for the period ending June 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Why BioCryst Pharmaceuticals Rose 8% on Thursday
August 05, 2021
The company's first commercial drug launch keeps exceeding expectations.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Product Safety
BioCryst Pharma Stock Heads Higher Thursday: Here's Why
August 05, 2021
BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) shares were trading higher Thursday after the company reported second-quarter financial results. The company reported revenue of...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
August 05, 2021
Gainers Ensysce Biosciences (NASDAQ:ENSC) shares rose 42.78% to $5.84 during Thursday's pre-market session. The company's market cap stands at $141.7 million....
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2021
August 03, 2021
Upgrades For SolarEdge Technologies Inc (NASDAQ:
Via
Benzinga
Analyzing BioCryst Pharmaceuticals's Unusual Options Activity
July 29, 2021
BioCryst Pharmaceuticals (NASDAQ:BCRX) shares experienced unusual options activity on Thursday. The stock price moved up to $16.93 following the option alert. Sentiment: BULLISH...
Via
Benzinga
Unusual Options Activity Insight: BioCryst Pharmaceuticals
July 23, 2021
On Friday, shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) saw unusual options activity. After the option alert, the stock price moved up to $17.1. Sentiment: BULLISH Option...
Via
Benzinga
BioCryst Outlines Pivotal Trial Designs For BCX9930 In Rare Blood Disorder
July 15, 2021
BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) has announced the designs for REDEEM-1 and REDEEM-2, two upcoming pivotal trials for its oral Factor D inhibitor,...
Via
Benzinga
BioCryst Shares 96-Week Orladeyo Data Highlighting 80% Reduction In HAE Attacks
July 12, 2021
BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) has announced 96-week data from the Phase 3 APeX-2 trial for Orladeyo (berotralstat), showing a sustained reduction in...
Via
Benzinga
18 Key Biopharma Catalysts To Keep An Eye On In Q3
July 10, 2021
Biopharma stocks underperformed in the first half of 2021, and several of these stocks could be in for a rebound in the coming months. Ne...
Via
Benzinga
Up 126% in 2021, Could BioCryst Pharmaceuticals Go Even Higher?
June 29, 2021
There's more than one opportunity for it to do so.
Via
The Motley Fool
9 Health Care Stocks With Unusual Options Alerts In Today's Session
June 22, 2021
This unusual options alert can help traders track potentially big trading opportunities. Traders often look for circumstances when the market estimation of an option diverges away...
Via
Benzinga
Analyzing BioCryst Pharmaceuticals's Unusual Options Activity
June 18, 2021
Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) saw some unusual options activity on Friday. Following the unusual option alert, the stock price moved down to $16.12. Sentiment...
Via
Benzinga
In Case Silver Gets Slammed More
June 18, 2021
The Fed is no longer your friend when it comes to silver. Time to consider limiting your downside risk here.
Via
Talk Markets
Topics
Economy
Exposures
Interest Rates
The Daily Biotech Pulse: Regeneron COVID-19 Antibody Cocktail Data, FDA Nod For Mallinckrodt, Molecular Partners IPO
June 16, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 15) Apellis Pharmaceuticals,...
Via
Benzinga
Exposures
COVID-19
Product Safety
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.